Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia

16 Dec 2016

Abstract excerpt

Abstract BACKGROUND Tyrosine kinase inhibitors (TKIs) are the cornerstone of successful clinical management of patients with chronic myeloid leukemia (CML). Quantitative monitoring of the percentage of the fusion transcript BCR-ABL1 (breakpoint cluster region–c-abl oncogene 1, non-receptor tyrosine kinase) BCR-ABL1IS (%BCR-ABL1IS) by reverse transcription–quantitative PCR (RT-qPCR) is the gold standard strategy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27979961
DOI: 10.1373/clinchem.2016.262824

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid LeukemiaPMID 27979961Read ↗

Digital PCR for BCR‐ABL1 Quantification in CML: Current Applications in Clinical PracticeSemantic proximity Read ↗

Next-Generation Digital Polymerase Chain Reaction Assay for BCR::ABL1 in Chronic Myeloid Leukemia: Comprehensive Validation Enabling Standardized Measurable Residual Disease DetectionSemantic proximity Read ↗

Analytical Performance Evaluation of a Digital Real‐Time PCR for Quantifying Major BCR :: ABL1 TranscriptsSemantic proximity Read ↗

Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE studySemantic proximity Read ↗

BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia.Semantic proximity Read ↗

Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid LeukemiaSemantic proximity Read ↗

Committed change of real-time quantitative PCR to droplet digital PCR for monitoring BCR :: ABL1 transcripts in tyrosine kinase inhibitor treated CMLSemantic proximity Read ↗

Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assaySemantic proximity Read ↗

Guidelines for the measurement of <i>BCR‐ABL1</i> transcripts in chronic myeloid leukaemiaSemantic proximity Read ↗

Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR?Semantic proximity Read ↗

Novel Multiplex Droplet Digital PCR Assays to Monitor Minimal Residual Disease in Chronic Myeloid Leukemia Patients Showing Atypical BCR-ABL1 TranscriptsSemantic proximity Read ↗

Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.